Inozyme Pharma (INZY) Stock Forecast, Price Target & Predictions
INZY Stock Forecast
Inozyme Pharma stock forecast is as follows: an average price target of $14.67 (represents a 144.50% upside from INZY’s last price of $6.00) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
INZY Price Target
The average price target for Inozyme Pharma (INZY) is $14.67 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $16.00 to $14.00. This represents a potential 144.50% upside from INZY's last price of $6.00.
INZY Analyst Ratings
According to 6 Wall Street analysts, Inozyme Pharma's rating consensus is 'Buy'. The analyst rating breakdown for INZY stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Inozyme Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Dae Gon Ha | Stifel Nicolaus | $16.00 | $5.21 | 207.10% | 166.67% |
| May 30, 2024 | Tiago Fauth | Wells Fargo | $14.00 | $4.51 | 210.42% | 133.33% |
| Apr 09, 2024 | Edward White | H.C. Wainwright | $14.00 | $5.87 | 138.50% | 133.33% |
The latest Inozyme Pharma stock forecast, released on Sep 11, 2024 by Dae Gon Ha from Stifel Nicolaus, set a price target of $16.00, which represents a 207.10% increase from the stock price at the time of the forecast ($5.21), and a 166.67% increase from INZY last price ($6.00).
Inozyme Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $16.00 | $16.00 | $14.67 |
| Last Closing Price | $6.00 | $6.00 | $6.00 |
| Upside/Downside | 166.67% | 166.67% | 144.50% |
In the current month, the average price target of Inozyme Pharma stock is $16.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 166.67% increase as opposed to Inozyme Pharma's last price of $6.00. This month's average price target is down 0.00% compared to last quarter, and up 9.07% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 30, 2024 | Wells Fargo | - | Overweight | Initialise |
| Apr 09, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 09, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Mar 23, 2023 | Jefferies | - | Buy | Upgrade |
| Jul 19, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Nov 30, 2021 | Needham | - | Buy | Initialise |
Inozyme Pharma's last stock rating was published by Wells Fargo on May 30, 2024. The company Initialise its INZY rating from "null" to "Overweight".
Inozyme Pharma Financial Forecast
Inozyme Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Inozyme Pharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. INZY's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Inozyme Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict INZY's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Inozyme Pharma's previous annual EBITDA (undefined) of $NaN.
Inozyme Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-27.46M | $-27.26M | $-27.46M | $-28.70M | $-26.98M | $-26.98M | $-24.60M |
| High Forecast | $-27.46M | $-27.26M | $-27.46M | $-28.70M | $-26.98M | $-25.14M | $-24.60M |
| Low Forecast | $-27.46M | $-27.26M | $-27.46M | $-28.70M | $-26.98M | $-28.21M | $-24.60M |
| Surprise % | - | - | - | - | - | - | - |
Inozyme Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. INZY's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Inozyme Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Inozyme Pharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to INZY last annual SG&A of $NaN (undefined).
Inozyme Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.44 | $-0.44 | $-0.44 | $-0.46 | $-0.44 | $-0.44 | $-0.40 |
| High Forecast | $-0.44 | $-0.44 | $-0.44 | $-0.46 | $-0.44 | $-0.41 | $-0.40 |
| Low Forecast | $-0.44 | $-0.44 | $-0.44 | $-0.46 | $-0.44 | $-0.46 | $-0.40 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Inozyme Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to INZY previous annual EPS of $NaN (undefined).
Inozyme Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
INZY Forecast FAQ
Is Inozyme Pharma a good buy?
Yes, according to 6 Wall Street analysts, Inozyme Pharma (INZY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of INZY's total ratings.
What is INZY's price target?
Inozyme Pharma (INZY) average price target is $14.67 with a range of $14 to $16, implying a 144.50% from its last price of $6. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Inozyme Pharma stock go up soon?
According to Wall Street analysts' prediction for INZY stock, the company can go up by 144.50% (from the last price of $6 to the average price target of $14.67), up by 166.67% based on the highest stock price target, and up by 133.33% based on the lowest stock price target.
Can Inozyme Pharma stock reach $9?
INZY's average twelve months analyst stock price target of $14.67 supports the claim that Inozyme Pharma can reach $9 in the near future.
What is Inozyme Pharma's current price target trend?
1 Wall Street analyst forecast a $16 price target for Inozyme Pharma (INZY) this month, up 166.67% from its last price of $6. Compared to the last 3 and 12 months, the average price target increased by 166.67% and increased by 144.50%, respectively.
What are Inozyme Pharma's analysts' financial forecasts?
Inozyme Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-78.563M (high $-76.723M, low $-79.789M), average SG&A $0 (high $0, low $0), and average EPS is $-1.268 (high $-1.239, low $-1.288). INZY's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-111M (high $-111M, low $-111M), average SG&A $0 (high $0, low $0), and average EPS is $-1.79 (high $-1.79, low $-1.79).